FIG. 2.

Expression of NF-κB p50, phospho-p65 (P-p65), and p65 subunits in nuclear-enriched fractions (NEF) of sciatic nerves from normal (N), 3-month diabetic (D), and sulfasalazine-treated 3-month diabetic (S) rats. A: Immunoreactivity of sciatic nerve nuclear-enriched fractions from three individual animals in each group. Blots were also incubated with anti-ERK2 to control for differences in sample loading. Numbers at the left of each panel depict the position of molecular mass markers (in kDa). B: Specificity of the signals was confirmed by immunoblotting of sciatic nerve extracts with dilutions of anti–NF-κB p50 or anti–NF-κB p65 antisera previously incubated in the presence (+P) or absence (−) of immunogenic peptides. C: Densitometry of immunoreactivity of NF-κB subunits relative to ERK2 for all animals analyzed in each group (n = 5–7) (Significantly different from **normal and ^∧∧untreated diabetics at P < 0.01 as calculated by ANOVA followed by Dunnett's test).